TY - JOUR
T1 - Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma
AU - Liebers, Nora
AU - Boumendil, Ariane
AU - Finel, Hervé
AU - Edelmann, Dominic
AU - Kobbe, Guido
AU - Baermann, Ben-Niklas
AU - Serroukh, Yasmina
AU - Blaise, Didier
AU - Beelen, Dietrich Wilhelm
AU - Solano, Carlos
AU - Itälä-Remes, Maija
AU - van Meerten, Tom
AU - Choi, Goda
AU - Schmidt, Susanne A C
AU - Kröger, Nicolaus
AU - Byrne, Jenny
AU - Tudesq, Jean-Jacques
AU - Ossami Saidy, Anna
AU - Nunes, Ana
AU - Siddiqi, Rubina
AU - Baro, Elande
AU - Zheng, Dan
AU - Kloos, Ioana
AU - Dreger, Peter
AU - Sureda, Anna
AU - Glass, Bertram
AU - Dietrich, Sascha
PY - 2025/5/5
Y1 - 2025/5/5
N2 - Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed or refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an analysis of 64 r/r MCL patients aged ≥50 years treated with brexu-cel in the ZUMA-2 study, matching them 1:1 by propensity score to 64 (out of 272) r/r MCL patients who underwent alloHCT using data from the EBMT registry. Median follow-up time was 36.5 and 34.1 months for the brexu-cel and matched alloHCT cohort, respectively. Brexu-cel patients had a significantly higher overall survival (OS, 81.3% vs 59.2%, HR: 0.39, p=0.004) and lower non-relapse mortality (3.6% vs 21.2%, p=0.015) one year after treatment. Chronic graft-vs-host disease occurred in 26.9% of alloHCT patients within the first year. However, long-term progression-free survival and OS remain comparable. Despite limitations of this non-randomized study, it indicates a superior safety profile for brexu-cel in r/r MCL.
AB - Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed or refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an analysis of 64 r/r MCL patients aged ≥50 years treated with brexu-cel in the ZUMA-2 study, matching them 1:1 by propensity score to 64 (out of 272) r/r MCL patients who underwent alloHCT using data from the EBMT registry. Median follow-up time was 36.5 and 34.1 months for the brexu-cel and matched alloHCT cohort, respectively. Brexu-cel patients had a significantly higher overall survival (OS, 81.3% vs 59.2%, HR: 0.39, p=0.004) and lower non-relapse mortality (3.6% vs 21.2%, p=0.015) one year after treatment. Chronic graft-vs-host disease occurred in 26.9% of alloHCT patients within the first year. However, long-term progression-free survival and OS remain comparable. Despite limitations of this non-randomized study, it indicates a superior safety profile for brexu-cel in r/r MCL.
U2 - 10.1158/2643-3230.BCD-24-0178
DO - 10.1158/2643-3230.BCD-24-0178
M3 - Article
C2 - 39913291
SN - 2643-3230
VL - 6
SP - 182
EP - 190
JO - Blood cancer discovery
JF - Blood cancer discovery
IS - 3
ER -